- Prescribing Advice for GPs - https://www.prescriber.org.uk -

SMC Update - October 2023

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Atogepant (Aquipta®) has been accepted for restricted use for the prophylaxis of migraine in adults who have at least 4 migraine days per month. The restriction limits use to patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.

Semaglutide (Wegovy®) has been accepted for restricted use as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS). In England, this product is recommended for use within a specialist weight management service.

Fenfluramine (Fintepla®) has been accepted for the treatment of seizures associated with Dravet syndrome as an add-on to other anti-epileptic medicines for patients 2 years of age and older. This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS). In England, this product is also subject to a commercial arrangement and as such it is expected prescribing would remain with a specialist.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.